PRVA

Privia Health Group, Inc.

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. was a former subsidiary of Brighton Health Group Holdings, LLC.

Privia Health Group, Inc. (PRVA) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Value (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
D+
Factor Score 1.6 / 5.0
Growth
C+
Factor Score 2.8 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
B
Factor Score 3.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 94.4
EV / EBITDA 43.2
Rev Growth YoY 13.2%
Gross Margin 9.9%
Price Return 3M 14.2%
Price Return 12M 1.4%
Catalyst Signal 0.00
Market Cap $3.1B
TTM Revenue $2.4B
Price / Sales 1.3
ROE 4.7%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 D+ (1.6) C+ (2.8) C+ (2.8) B (3.2) C+ (2.6) C+ (2.6)
2026-11-07 D+ (1.5) C+ (2.8) C+ (2.8) C+ (2.8) C+ (2.7) C+ (2.5)
2026-10-31 D+ (1.6) B- (3.1) C+ (2.8) C (2.3) C+ (2.7) C (2.5)
2026-10-24 D+ (1.6) B- (3.0) C+ (2.8) C- (2.1) C+ (2.6) C (2.4)
2026-10-17 D+ (1.6) B- (3.0) C+ (2.8) C- (2.1) C+ (2.6) C (2.4)
Page 1 of 8
…